Oct 17- Pfizer Inc said on Monday it plans to begin shipping its biosimilar version of Johnson& Johnson's blockbuster rheumatoid arthritis drug Remicade in late November at a 15 percent discount to current wholesale prices. The Pfizer drug, to be sold under the name Inflectra, is already available in Europe and other overseas markets and would be the second...
Oct 17- Depomed Inc said activist investor Starboard Value LP, which owns 9.8 percent of the drugmaker, had dropped its bid to oust the company's board. The company said a special shareholder meeting scheduled for Nov. 15 was canceled. Depomed, which has six directors on its board, said Starboard would appoint three independent directors- James Fogarty, Robert...
TRENTON, N.J.— Drugmaker Pfizer said Monday that it will launch a less-expensive version of rival Johnson& Johnson's blockbuster immune disorder drug, Remicade. Pfizer Inc.' s version, called Inflectra, will hit pharmacies in late November. New York- based Pfizer said it will sell Inflectra at a 15 percent discount to the list price for Remicade.
*FDA puts study on hold after joint damage observed in a patient. *Brokerage cuts Regeneron price target to $513 from $530. Following the FDA decision, Regeneron has completed an unplanned interim review of data and has stopped dosing patients, the companies said.
The Food and Drug Administration's decision followed a case of a type of joint inflammation in a patient who also had advanced osteoarthritis and was given a high dose of the injectable drug, fasinumab. Following the FDA decision, Regeneron has completed an unplanned interim review of data and has stopped dosing patients, the companies said on Monday.
Ariad Pharmaceuticals plunged as much as 15 percent after Sen. Bernie Sanders criticized the price of the company's leukemia drug.
Martin Shkreli's lawyers previously suggested that his defense would be based on the claim that he had been relying on the advice of his lawyer.
Canadian drugmaker Valeant Pharmaceuticals said Friday it will increase the list prices of products in some of its portfolios by 2 percent to 9 percent.
REGULATIONS WILL ALLOW CUBAN PHARMACEUTICAL COMPANIES TO APPLY FOR U.S.
Technology companies are rising as investors were pleased with economic reports from the U.S. and China. CHINA INFLATION: Reports suggested consumers in China are starting to spend more, while the national producer price index, which measures inflation, rose for the first time since 2012. That could result in factories in China starting to pass rising costs to...
The "Fast Money Halftime Report" traders, Kevin O'Leary, O'Shares Chairman and "Shark Tank" star, and Ian Winer, Wedbush, share their takes on the health care sector, including Merck after Bank of America's call to upgrade the stock to buy.
Oct 13- Bowing to public pressure, the U.S. Drug Enforcement Administration said on Thursday it had delayed a decision on whether to classify the botanical substance kratom, which is available online in the United States as a dietary supplement, as a dangerous drug with no medicinal use. The leaves of the kratom tree, native to Southeast Asia, can be used as a...
Jefferies downgrades Pfizer to hold from buy.
LONDON, Oct 13- Pfizer suffered a setback in Britain on Thursday when the Court of Appeal in London ruled against it in a patent case over the use of its $5 billion- a-year drug Lyrica for pain relief. Pfizer said it was disappointed by the decision and would seek a further appeal. While the original patent on pregabalin has expired, Pfizer was awarded a secondary...
Dr. Peter Bach, Memorial Sloan Kettering physician, discusses how copay assistance programs are actually causing drug prices to rise.
CNBC's Meg Tirrell discusses implications surrounding co-pay assistance programs.
CNBC's Bertha Coombs reports the latest troubles in health care, including why shares of Humana are sinking.
Chris Raymond, Raymond James analyst, discusses how to trade the biotech sell-off amid election season.
Researchers are working on opioids with all the painkilling power of current drugs but with less risk of addiction or overdose.
Federal health officials and the drug company Mylan are refusing to explain why full rebates for EpiPen are being delayed.